## Four New Eudesmane Sesquiterpenoid Lactones from Chloranthus serratus

by Fei Teng<sup>a</sup>)<sup>b</sup>), Hui-Min Zhong<sup>b</sup>), Chang-Xiang Chen<sup>a</sup>), and Hai-Yang Liu\*<sup>a</sup>)

<sup>a</sup>) State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204, P. R. China

(phone: +86-871-5223245; fax: +86-871-5223246; e-mail: haiyangliu@mail.kib.ac.cn)

Four new eudesmane sesquiterpenoids endowed with an  $\alpha,\beta$ -unsaturated  $\gamma$ -lactone five-membered ring, serralactones A – D (1–4, resp.), along with seven known sesquiterpenoids, were isolated from the whole plant *Chloranthus serratus*. Their structures and relative configurations were established on the basis of extensive spectroscopic analyses.

**Introduction.** – The genus *Chloranthus* (Chloranthaceae), which includes *ca.* 15 species, is mainly distributed in the east of Asia and has attracted considerable attention as a source of new sesquiterpenoids with diverse structures and biological properties [1][2]. *Chloranthus serratus* (Thunb.) Roem. Et Schult., with the Chinese name 'Jiji', has long been used as treatment to activate blood circulation against stasis in Chinese folk medicine to cure injuries from falls, furuncle, tumefaction, and emmeniopathy [3]. Previous chemical investigations of this plant resulted in the isolation of various compounds including amides, sesquiterpenoids, and lindenane-type sesquiterpenoid dimers [4–10]. In our current investigation, four new eudesmane sesquiterpenoids with an  $\alpha,\beta$ -unsaturated  $\gamma$ -lactone five-membered ring, serralactones A–D (1–4), and seven known sesquiterpenoids, neolitacumone B (5) [11], glechomanolide [12], zedoalactone A [13], oplodiol [14], cyperusol C [15], eudesm-4(15)-ene-1 $\beta$ ,7,11-triol [16] and eudesm-3-ene-1 $\beta$ ,7,11-triol [16] were isolated from the whole plants of *Chloranthus serratus*. The details of the isolation and structural elucidation of serralactones A–D (1–4, resp.), are discussed in this article.

**Results and Discussion.** – Serralactone A (1) was obtained as a white amorphous powder, and its molecular formula was established as  $C_{15}H_{20}O_3$  by the HR-ESI-MS spectrum (m/z 249.1490, [M+H]<sup>+</sup>; calc. 249.1490). The absorption bands in the IR spectrum at 1744 and 1681 cm<sup>-1</sup>, and the UV maximum at 219 nm indicated the presence of an  $\alpha$ , $\beta$ -unsaturated  $\gamma$ -lactone moiety in 1 similar to neolitacumone B (5) [11]. The <sup>1</sup>H-NMR spectrum ( $Table\ 1$ ) showed the presence of three Me *singlets* at  $\delta(H)$  0.96, 1.71, 1.85 (Me(14), Me(15), and Me(13)<sup>1</sup>), resp.), and of one olefinic H-atom at  $\delta(H)$  5.40 (H–C(3)). The <sup>13</sup>C-NMR spectrum ( $Table\ 2$ ) displayed 15 C-atom signals which were classified by a DEPT experiment into three Me, three CH<sub>2</sub>, four CH

b) College of Chemistry and Molecular Engineering, Qingdao University of Science and Technology, Qingdao 266042, P. R. China

<sup>1)</sup> Arbitrary numbering. For systematic names, see *Exper. Part*.

groups (including two O-bearing and an olefinic CH group), and five quaternary C-atoms (including a lactone group and three olefinic C-atoms). Therefore, **1** was clearly recognized as an eudesm-7(11)-enolide sesquiterpene. Comprehensive analysis of NMR and mass spectra suggested that **1** was a C=C bond isomer of neolitacumone B (**5**) [11]. The position of the C(3)=C(4) bond was deduced from the HMBC correlations (*Fig.*) of  $\delta$ (H) 3.57 (*dd*, H–C(1)) with  $\delta$ (C) 32.3 (*t*, C(2)), 121.1 (*d*, C(3)), 47.3 (*d*, C(5)), 42.0 (*t*, C(9)), 38.9 (*s*, C(10)), and 10.0 (*q*, Me(14)), and  $\delta$ (H) 5.40 (br. *s*, H–C(3)) with  $\delta$ (C) 74.9 (*d*, C(1)), and 20.8 (*q*, C(15)), and  $\delta$ (H) 1.71 (*s*, Me(15)) with  $\delta$ (C) 121.1 (*d*, C(3)), 132.9 (*s*, C(4)), and 47.3 (*d*, C(5)). The relative configuration of **1** was established by a ROESY experiment, in which the correlations from Me(14) to H<sub> $\beta$ </sub>–C(6) and H–C(8) indicated that they were on the same side of the ring and were assigned being  $\beta$ -oriented. Consequently, the ROESY correlations of H<sub> $\alpha$ </sub>–C(6)/H–C(5), and H–C(5)/H–C(1) suggested that H–C(1) and H–C(5) have  $\alpha$ -orientation. Thus, compound **1** was identified as 1 $\beta$ -hydroxyeudesma-3,7(11)-dien-12,8 $\alpha$ -olide.




Figure.  ${}^{1}H, {}^{1}H-COSY$  (—) and selected HMBC (H  $\rightarrow$  C) of 1-4

Table 1. <sup>1</sup>*H-NMR Data of Compounds*  $\mathbf{1}-\mathbf{4}^1$ ).  $\delta$  in ppm, J in Hz.

	<b>1</b> a)c)	<b>2</b> <sup>a</sup> ) <sup>c</sup> )	<b>3</b> a)c)	<b>3</b> <sup>b</sup> ) <sup>c</sup> )	<b>4</b> <sup>a</sup> ) <sup>d</sup> )	<b>4</b> <sup>b</sup> ) <sup>d</sup> )
H-C(1)	3.57 (dd,	3.37 (dd,	3.19 (dd,	3.00 – 2.96 (m)	5.65 (d,	5.54 (d,
	J = 6.3, 10.1)	J = 4.4, 11.9	J = 3.5, 11.6		J = 10.0)	J = 10.0)
$H_a$ -C(2)	2.37-2.33 (m)	$1.69 - 1.65 \ (m)$	1.53 - 1.49 (m)	1.32-1.29 (m)	5.88 (dd,	5.73 (dd,
					J = 5.5, 10.0	J = 5.4, 10.0
$H_{\beta}-C(2)$	2.06-2.02 (m)	2.12-2.08 (m)	2.00-1.96 (m)	1.75 - 1.72 (m)		
$H_a$ -C(3)	5.40 (br. s)	1.55 - 1.49 (m)	1.57 - 1.54 (m)	1.36-1.34 (m)	3.69(d,	3.56 (t,
					J = 5.5)	J = 5.4)
$H_{\beta}$ -C(3)		$1.74 - 1.70 \ (m)$	1.76 - 1.72 (m)	1.55 - 1.52 (m)		
H-C(5)	2.00-1.97 (m)	1.31 (dd,	1.12 (dd,	0.93 (dd,		
		J = 3.8, 13.5)	J = 2.6, 13.1)	J = 2.5, 12.9		
$H_a$ -C(6)	2.92 (dd,	2.91 (dd,	2.56-2.54 (m)	2.36-2.34 (m)	2.77(d,	2.66(d,
	J = 3.9, 13.7	J = 3.8, 13.5)			J = 15.0)	J = 11.6)
$H_{\beta}$ -C(6)	2.21 (t,	2.51 (t,	2.81 (dd,	2.61 (dd,	2.91 (d,	2.81 (d,
,	J = 13.7)	J = 13.5)	J = 2.6, 13.1)	J = 2.5, 12.9)	J = 15.0)	J = 11.6)
H-C(8)	4.91 (dd,	5.00 (dd,		1.11 - 1.09 (m)	4.94 (dd,	5.04 (dd,
	J = 6.8, 10.4	J = 6.3, 11.8)			J = 6.4, 11.9	J = 6.5, 12.0
$H_a$ -C(9)	$1.01 - 0.99 \ (m)$	0.78 (t, J = 11.8)	1.33-1.30 (m)	2.42-2.39 (m)	1.91 (dd,	1.80 (dd,
					J = 6.4, 11.9	J = 6.5, 12.0
$H_{\beta}-C(9)$	2.75 (dd,	3.16 (dd,	2.60-2.58 (m)		2.16 (t,	1.95 (t,
,	J = 6.8, 10.4	J = 6.3, 11.8)			J = 11.9)	J = 12.0)
Me(13)	1.85(s)	1.80(s)	1.81 (s)	1.68(s)	1.81 (s)	1.69(s)
Me(14)	0.96(s)		1.31 (s)	1.14 (s)	1.36(s)	1.21(s)
$H_a - C(14)$		4.43 (d, J = 12.5)				
$H_{b} - C(14)$		3.76 (d, J = 12.5)				
Me(15)	1.71(s)	1.21(s)	1.25(s)	1.09(s)	1.19(s)	1.11(s)
1-OH	. ,	. ,	. ,	4.44 (d, J = 5.2)		
3-OH						5.45 (d,
						J = 5.6)
4-OH				4.04(s)		4.75 (s)
5-OH				. ,		4.60(s)
8-OH				7.01(s)		. ,

<sup>&</sup>lt;sup>a</sup>) Recorded in (D<sub>4</sub>)MeOH. <sup>b</sup>) Recorded in (D<sub>6</sub>)DMSO. <sup>c</sup>) Recorded at 500 MHz. <sup>d</sup>) Recorded at 400 MHz.

Serralactone B (2), a white amorphous power, was shown to have the molecular formula  $C_{15}H_{22}O_5$  on the basis of the HR-ESI-MS spectrum (m/z 305.1368, [M+Na]<sup>+</sup>; calc. 305.1364). The <sup>13</sup>C-NMR (DEPT) spectrum ( $Table\ 2$ ) showed 15 C-atom resonances assignable to a CO group ( $\delta(C)$  177.3), a tetrasubstituted C=C bond ( $\delta(C)$  120.7, 165.9), two Me, a HO-CH<sub>2</sub> ( $\delta(C)$  61.4), four CH<sub>2</sub>, and two CH groups (including two O-bearing CH groups ( $\delta(C)$  79.9, 80.1)), as well as two quaternary C-atoms (including one O-bearing C-atom ( $\delta(C)$  71.1)). The data suggested that **2** is an eudesm-7(11)-enolide sesquiterpenoid possessing the same B and C rings as **1**, but a different A ring. The constitutional formula of **2** was determined on the basis of spectroscopic analyses and confirmed by <sup>1</sup>H, <sup>1</sup>H-COSY and HMBC (Fig.). The fragment H-C(1)-CH<sub>2</sub>(2)-CH<sub>2</sub>(3)<sup>1</sup>) is positioned between C(10) and C(4) based on the observed <sup>1</sup>H, <sup>1</sup>H-COSY correlations of H-C(2) with H-C(1) and H-C(3) and

Table 2. <sup>13</sup>C-NMR Data of Compounds  $1-4^1$ ).  $\delta$  in ppm.

	1a)c)	2 <sup>a</sup> ) <sup>c</sup> )	3a)c)	<b>3</b> <sup>b</sup> ) <sup>c</sup> )	<b>4</b> <sup>a</sup> ) <sup>d</sup> )	<b>4</b> <sup>b</sup> ) <sup>d</sup> )
H-C(1)	74.9 (d)	80.1 (d)	80.1 (d)	77.8 (d)	133.5 (d)	134.0 (d)
$CH_2(2)$ or $H-C(2)$	32.3(t)	28.2(t)	27.3(t)	26.6(t)	126.3(d)	125.4(d)
$H-C(3)$ or $CH_2(3)$	121.1(d)	39.9(t)	40.1(t)	39.9(t)	72.1(d)	71.3(d)
C(4)	132.9(s)	71.1~(s)	71.8(s)	69.7(s)	72.3(s)	71.6(s)
H-C(5) or $C(5)$	47.3(d)	52.8(d)	54.7 (d)	53.2 (d)	79.1 (s)	79.0(s)
$CH_2(6)$	25.3(t)	24.1(t)	22.9(t)	21.8(t)	29.5(t)	29.3(t)
C(7)	162.0(s)	165.9(s)	164.1 (s)	162.8 (s)	161.7(s)	163.4 (s)
H-C(8) or $C(8)$	78.5(d)	79.9(d)	105.7(s)	104.2 (s)	78.5(d)	78.0(d)
$CH_2(9)$	42.0(t)	41.5(t)	51.4 (t)	50.4(t)	39.2 (t)	39.0(t)
C(10)	38.9(s)	44.7(s)	41.4(s)	40.1~(s)	40.5(s)	40.0(s)
C(11)	120.6(s)	120.7(s)	121.9(s)	119.7(s)	122.7(s)	120.6(s)
C(12)	174.8 (s)	177.3(s)	174.6 (s)	171.8 (s)	175.7(s)	172.1 (s)
Me(13)	8.3(q)	8.0 (q)	8.0 (q)	7.8(q)	8.1 (q)	8.0 (q)
Me(14)	10.0 (q)	61.4(t)	13.6(q)	13.0 (q)	25.2(q)	25.4(q)
Me(15)	20.8(q)	29.1 (q)	30.0(q)	29.9 (q)	22.9(q)	22.6 (q)

<sup>&</sup>lt;sup>a)</sup> Recorded in  $(D_4)$ MeOH. <sup>b)</sup> Recorded in  $(D_6)$ DMSO. <sup>c)</sup> Recorded at 125 MHz. <sup>d)</sup> Recorded at 100 MHz.

the HMBC correlations of H-C(5) with C(1), C(3), C(4), C(7), C(9), C(10), and C(14). The  $HO-CH_2$  group was placed at C(10) taking into account the HMBC correlations between  $CH_2(14)$  to C(1), C(5), C(9), and C(10). The relative configuration of **2** was deduced from the ROESY spectrum. The NOE interactions of  $CH_2(14)$  with  $H_\beta-C(2)$ ,  $H_\beta-C(6)$  and H-C(8), and of H-C(8) with  $H_\beta-C(9)$  suggested that they are placed on the same side of the molecule. Moreover, the cross peaks for  $H_\alpha-C(2)/Me(15)$ ,  $H_\alpha-C(9)/H-C(5)$ , H-C(5)/H-C(1) indicated that H-C(1), H-C(5), and Me(15) lie on the opposite face. Hence, we have established that **2** is  $1\beta$ ,  $4\beta$ , 14-trihydroxyeudesm-7(11)-en-12,  $8\alpha$ -olide.

Serralactone C (3) was obtained as a white amorphous power. The HR-ESI-MS spectrum showed a pseudo-molecular ion peak at m/z 305.1373 ( $[M + Na]^+$ ; calc. 305.1364) corresponding to the same molecular formula C<sub>15</sub>H<sub>22</sub>O<sub>5</sub> as that of compound 2. The <sup>1</sup>H- and <sup>13</sup>C-NMR spectra of 3 (*Tables 1* and 2) were similar to those of 2, except for the absence of the  $HO-CH_2$  group and the presence of a Me group at  $C(10)^1$ ) and a lactol group at C(8), as determined by the resonances at  $\delta$ (H) 1.31 (s) and  $\delta$ (C) 105.7 (s). In the HMBC spectrum (Fig.), the correlations from Me(14) to C(1), C(5), C(9), and C(10), and from both CH<sub>2</sub>(6) and CH<sub>2</sub>(9) to C(8) confirmed this deduction. The relative configuration of 3 was identical with the one of 2, leaving open only C(8) of the lactol group. While it was impossible to determine the configuration of 8-OH in the lactol group due to the absence of ROESY correlations of the 8-OH signal and the other H-atoms resonance in (D<sub>4</sub>)methanol, crucial NOE correlations between  $\delta(H)$ 1.14 (s, Me(14)) and  $\delta$ (H) 4.44 (d, 1-OH), 4.04 (s, 4-OH), and 7.01 (s, 8-OH) were observed in (D<sub>6</sub>)DSMO, which revealed that they are positioned on the same side of the molecule. Hence, the structure of 3 is assumed to be  $1\beta,4\beta,8\beta$ -trihydroxyeudesm-7(11)-en-12,8 $\alpha$ -olide.

Serralactone D (4) was isolated as a white amorphous power with the molecular formula  $C_{15}H_{20}O_5$  as deduced from the HR-ESI-MS spectrum (m/z 303.1202, [M+]Na]+; calc. 303.1208). The IR and UV spectra suggested that also 4 contained an  $\alpha,\beta$ -unsaturated  $\gamma$ -lactone moiety. The <sup>1</sup>H- and <sup>13</sup>C-NMR spectra of **4** (*Tables 1* and 2) displayed a CO group, a disubstituted CH = CH group, a tetrasubstituted C=C bond, three Me, two CH<sub>2</sub>, and two O-bearing CH groups, as well as three quaternary C-atoms (including two O-bearing ones). These informations pointed to 4 being an eudesm-7(11)-enolide sesquiterpene possessing the same B and C rings as 1 and 2, but a different A ring. The disubstituted CH=CH group was assigned to be placed between C(1) and  $C(2)^1$ ) based on the long-range correlations of H-C(1) with C(5), C(9), C(10) and Me(14), of H-C(2) with C(1) and C(10) in the HMBC spectrum (Fig.). Due to the presence of the  ${}^{1}H$ ,  ${}^{1}H$ -COSY correlation (Fig.) of H-C(3)/H-C(2) and the HMBC correlations of H-C(1)/C(3), H-C(1)/C(5), H-C(2)/C(4), Me(14)/C(5), Me(15)/C(3), Me(15)/C(4) and Me(15)/C(5), the three OH groups were placed at C(3), C(4), and C(5), respectively. The relative configuration of 4 was determined on the basis of ROESY data. The ROESY interactions of Me(14) with  $H_{\beta}$ -C(6), H-C(8), and  $H_{\beta}-C(9)$  suggested that they are placed on the same side of the molecule. Moreover, the ROESY correlations for  $H_a$ –C(6)/Me(15) and for Me(15)/Me(15)H-C(3) disclosed that both H-C(3) and Me(15) lie on the opposite face. In order to determine the relative configuration of 5-OH, NMR experiments were reperformed in (D<sub>6</sub>)DMSO. Key ROESY correlations of  $\delta$ (H) 1.21 (s, Me(14)) with 5.45 (d, 3-OH), 4.75 (s, 4-OH), and 4.60 (s, 5-OH) were observed, which implied that they were placed on the  $\beta$  side. Therefore, compound 4 was established as  $3\beta$ ,  $4\beta$ ,  $5\beta$ -trihydroxyeudesma-1,7(11)-dien- $12,8\alpha$ -olide.

## **Experimental Part**

General. Semi-preparative HPLC: Agilent 1100 apparatus; Zorbax SB-C-18 column (Agilent, 9.4 mm × 25 cm). Column chromatography (CC): on silica gel (SiO<sub>2</sub>; 200–300 mesh, Qingdao Marine Chemical Inc, P. R. China), or on silica gel H (10–40 μm, Qingdao Marine Chemical Inc.), or Sephadex LH-20 (Pharmacia). Fractions were monitored by TLC and spots were visualized by heating the silica gel plates sprayed with 10%  $H_2SO_4$  in EtOH. [a]<sub>D</sub>: JASCO DIP-370 digital polarimeter. UV Spectra: Shimadzu UV-2401 PC spectrophotometer. IR Spectra: Bio-Rad FTS-135 spectrometer, KBr pellets; in cm<sup>-1</sup>.  $^{1}$ H- and  $^{13}$ C-NMR spectra: Bruker AM-400 instrument (400/100 MHz) and Bruker DRX-500 instrument (500/125 MHz);  $\delta$  in ppm rel. to TMS as internal standard, J in Hz. EI-MS: VG Auto Spec-3000 mass spectrometer; in m/z. HR-ESI-MS: API Qstar Pulsar LC/TOF instrument.

Plant Material. The whole plants of C. serratus were collected in July 2007 from Xinning, Hunan Province, P. R. China, and identified by Dr. Jian-Ying Xiang of Kunming Institute of Botany. A voucher specimen (No. 200702) has been deposited at the State Key Laboratory of Phytochemistry and Plant Resources in West China.

Extraction and Isolation. Dried and powdered whole plants of C. serratus (8 kg) were extracted with 70% acetone/H<sub>2</sub>O (5 × 50 l) at r.t. The extract was concentrated under reduced pressure to obtain a dark crude extract (200 g), which was then subjected to a column of D-941 gel eluted with 70% and 90% aq. EtOH. The evaporated 70% EtOH fraction was separated on a SiO<sub>2</sub> column eluted with petroleum ether (PE)/AcOEt (10:1-1:1) to yield eight fractions ( $Frs.\ I-VIII$ ).  $Fr.\ I$  (10.0 g) was repeatedly chromatographed over SiO<sub>2</sub> (PE/acetone 10:1), and semi-preparative HPLC (MeCN/H<sub>2</sub>O 30:70) to afford 1 (10 mg), and zedoalactone A (21 mg).  $Fr.\ V$  (5.8 g) was repeatedly separated on SiO<sub>2</sub> using CHCl<sub>3</sub>/MeOH (100:1) to afford 2 (8 mg), 3 (9 mg), 4 (13 mg), and 5 (42 mg).  $Fr.\ VI$  (7.0 g) was subjected to SiO<sub>2</sub> column using CHCl<sub>3</sub>/MeOH (90:1) as eluent, then purified on  $Sephadex\ LH$ -20 (MeOH) to yield

glechomanolide (8 mg), oplodiol (35 mg), and cyperusol C (28 mg). Fr. VII was first chromatographed over SiO<sub>2</sub> using CHCl<sub>3</sub>/MeOH (85:1) as eluent, and then purified on semi-preparative HPLC (MeCN/  $\rm H_2O$ , 30:70; flow rate: 3 ml/min; UV detector at 220 nm) to give eudesm-4(15)-ene-1 $\beta$ ,7,11-triol (42 mg), and eudesm-3-ene-1 $\beta$ ,7,11-triol (15 mg).

Serralactone A (=1β-Hydroxyeudesma-3(4),7(11)-dien-12,8α-olide = (4aS\*,8R\*,8aR\*,9aS\*)-4a,7,8,8a,9,9a-Hexahydro-8-hydroxy-3,5,8a-trimethylnaphtho[2,3-b]furan-2(4H)-one; 1). White amorphous power. [ $\alpha$ ]<sub>D</sub><sup>21</sup> = +31.91 ( $\varepsilon$  = 0.09, MeOH). UV (MeOH): 219. IR (KBr): 3435, 2924, 1744, 1681, 1034.  $^{1}$ H- and  $^{13}$ C-NMR: *Tables 1* and 2. ESI-MS: 287 (13, [M + K] $^{+}$ ). HR-ESI-MS: 249.1490 ([M + H] $^{+}$ ,  $C_{15}$ H<sub>21</sub>O<sub>3</sub> $^{+}$ ; calc. 249.1490).

Serralactone B (=1β,4β,14-Trihydroxyeudesm-7(11)-en-12,8α-olide = (4aR\*,5S\*,8R\*,8aR\*,9aS\*)-4a,5,6,7,8,8a,9,9a-Octahydro-5,8-dihydroxy-8a-(hydroxymethyl)-3,5-dimethylnaphtho[2,3-b]furan-2(4H)-one; **2**). White amorphous power. [α] $_{\rm D}^{\rm 2D}$  = +17.68 (c = 0.07, MeOH). UV (MeOH): 220. IR (KBr): 3429, 2930, 1744, 1679, 1036.  $^{\rm 1}$ H- and  $^{\rm 13}$ C-NMR: Tables 1 and 2. EI-MS: 282 (1,  $M^+$ ), 264 (12, [M - H<sub>2</sub>O] $^+$ ), 246 (36, [M - 2 H<sub>2</sub>O] $^+$ ), 228 (37, [M - 3 H<sub>2</sub>O] $^+$ ), 216 (100), 188 (20), 160 (35), 145 (26), 105 (23), 91 (26), 77 (19). HR-ESI-MS: 305.1368 ([M + Na] $^+$ ,  $C_{15}$ H<sub>22</sub>NaO $_{5}$ ; calc. 305.1364).

Serralactone C (=1β,4β,8β-Trihydroxyeudesm-7(11)-en-12,8α-olide = (4aR\*,5S\*,8R\*,8aR\*,9aS\*)-4a,5,6,7,8,8a,9,9a-Octahydro-5,8,9a-trihydroxy-3,5,8a-trimethylnaphtho[2,3-b]furan-2(4H)-one; **3**). White amorphous power. [α] $_{0}^{1}$  = +0.0 (c = 0.07, MeOH). UV (MeOH): 221. IR (KBr): 3417, 2946, 1737, 1689, 1242, 1142.  $_{0}^{1}$ H- and  $_{0}^{1}$ C-NMR: Tables 1 and 2. EI-MS: 282 (2,  $_{0}^{1}$ H), 264 (19, [ $_{0}^{1}$ H -  $_{0}^{1}$ H), 246 (40, [ $_{0}^{1}$ H -  $_{0}^{1}$ H), 218 (100), 203 (32), 173 (66), 161 (52), 147 (35), 135 (36), 121 (41), 107 (26), 91 (38), 77 (25). HR-ESI-MS: 305.1373 ([ $_{0}^{1}$ H -  $_{0}^{1}$ H,  $_{0}^{$ 

Serralactone D (= 3β,4β,5β-Trihydroxyeudesma-1,7(11)-dien-12,8α-olide = (4aR\*,5S\*,68\*,8a-S\*,9aS\*)-4a,5,6,8a,9,9a-Hexahydro-4a,5,6-trihydroxy-3,5,8a-trimethylnaphtho[2,3-b]furan-2(4H)-one; **4**). White amorphous power. [α] $_{0}^{20}$  = +145.16 (c = 0.06, MeOH). UV (MeOH): 220. IR (KBr): 3429, 2929, 1732, 1684, 1041.  $_{0}^{1}$ H- and  $_{0}^{1}$ C-NMR: Tables 1 and 2. EI-MS: 280 (1, M+), 264 (8, [M – H<sub>2</sub>O] $_{0}^{+}$ ), 244 (6, [M – 2 H<sub>2</sub>O] $_{0}^{+}$ ), 234 (100), 216 (29), 201 (19), 173 (27), 163 (24), 145 (28), 123 (52), 100 (36), 91 (18), 77 (15). HR-ESI-MS: 303.1202 ([M + Na] $_{0}$ +, C<sub>15</sub>H<sub>20</sub>NaO $_{0}$ +; calc. 303.1208).

## REFERENCES

- [1] Z.-K. Zhou, Acta Bot. Yunnan. 1993, 15, 321.
- [2] C.-M. Cao, Y. Peng, Q.-W. Shi, P.-G. Xiao, Chem. Biodiversity 2008, 5, 219.
- [3] Jiangsu New Medicinal College, 'Dictionary of Chinese Materia Medica', Shanghai Scientific and Technological Press, Shanghai, 1977, p. 234.
- [4] T. Takemoto, M. Uchida, K. Koike, Y. Hoshina, G. Kusano, Chem. Pharm. Bull. 1975, 23, 1161.
- [5] T. Takemoto, M. Uchida, G. Kusano, Chem. Pharm. Bull. 1976, 24, 531.
- [6] J. Kawabata, Y. Fukushi, S. Tahara, J. Mizutani, Agric. Biol. Chem. 1985, 49, 1479.
- [7] J. Kawabata, J. Mizutani, Agric. Biol. Chem. 1989, 53, 203.
- [8] J. Kawabata, E. Fukushi, J. Mizutani, Phytochemistry 1993, 32, 1347.
- [9] J. Kawabata, J. Mizutani, Phytochemistry 1992, 31, 1293.
- [10] T. Yuan, C.-R. Zhang, S.-P. Yang, S. Yin, W.-B. Wu, L. Dong, J.-M. Yue, J. Nat. Prod. 2008, 71, 2021.
- [11] F.-R. Chang, T.-J. Hsieh, T.-L. Huang, C.-Y. Chen, R.-Y. Kuo, Y.-C. Chang, H.-F. Chiu, Y.-C. Wu, J. Nat. Prod. 2002, 65, 255.
- [12] J. Kawabata, S. Tahara, J. Mizutani, Agric. Biol. Chem. 1981, 45, 1447.
- [13] I. Takano, I. Yasuda, K. Takeya, H. Itokawa, Phytochemistry 1995, 40, 1197.
- [14] T. V. Sung, B. Steffan, W. Steglich, G. Klebe, G. Adam, Phytochemistry 1992, 31, 3515.
- [15] F. Xu, T. Morikawa, H. Matsuda, K. Ninomiya, M. Yoshikawa, J. Nat. Prod. 2004, 67, 569.
- [16] M. Okasaka, Y. Takaishi, Y. Kashiwada, O. K. Kodzhimatov, O. Ashurmetov, A. J. Lin, L. M. Consentino, K.-H. Lee, *Phytochemistry* 2006, 67, 2635.

Received December 17, 2008